# Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei

> **NCT04982146** · PHASE1 · UNKNOWN · sponsor: **Maimónides Biomedical Research Institute of Córdoba** · enrollment: 10 (estimated)

## Conditions studied

- Pseudomyxoma Peritonei

## Interventions

- **DRUG:** Bromelin
- **DRUG:** N-Acetylcysteine

## Key facts

- **NCT ID:** NCT04982146
- **Lead sponsor:** Maimónides Biomedical Research Institute of Córdoba
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-13
- **Primary completion:** 2022-05-16
- **Final completion:** 2023-05-16
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2022-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982146, "Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04982146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*